Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   35554   clinical trials with a EudraCT protocol, of which   5841   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    An open, phase IIIb, randomized, multicentric clinical trial to compare the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ DTPa-IPV vaccine versus co-administration of GSK Biologicals’ DTPa vaccine and Sanofi-Pasteurs’ IPV vaccine at different injection sites, to healthy children at 2, 4 and 6 months of age.

    Summary
    EudraCT number
    2015-001508-71
    Trial protocol
    Outside EU/EEA  
    Global end of trial date
    23 Jan 2007

    Results information
    Results version number
    v1(current)
    This version publication date
    27 Apr 2016
    First version publication date
    10 Jul 2015
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    104871
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT00290342
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    GlaxoSmithKline Biologicals
    Sponsor organisation address
    Rue de l’Institut 89, Rixensart, Belgium, B-1330
    Public contact
    Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com
    Scientific contact
    Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    Yes
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    16 Nov 2007
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    23 Jan 2007
    Global end of trial reached?
    Yes
    Global end of trial date
    23 Jan 2007
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To demonstrate the non-inferiority of the DTPa-IPV vaccine to DTPa and IPV vaccines administered separately, in terms of antibody response against all vaccine antigens, one month after the three-dose primary vaccination course.
    Protection of trial subjects
    The vaccines were observed closely for at least 30 minutes, with appropriate medical treatment readily available in case of a rare anaphylactic reaction following the administration of vaccines.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    10 Jan 2006
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Korea, Republic of: 458
    Worldwide total number of subjects
    458
    EEA total number of subjects
    0
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    458
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    0
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    Of the 458 subjects enrolled in the study, 6 subjects (5 from Infanrix-IPV Group and 1 from Infanrix + IMOVAX Polio Group) were not administered the study vaccine due to consent withdrawal from parents/guardians and received an elimination code.

    Pre-assignment period milestones
    Number of subjects started
    458
    Number of subjects completed
    452

    Pre-assignment subject non-completion reasons
    Reason: Number of subjects
    Consent withdrawn by subject: 6
    Period 1
    Period 1 title
    Overall period
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Infanrix-IPV Group
    Arm description
    -
    Arm type
    Experimental

    Investigational medicinal product name
    Infanrix™-IPV
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Subjects received 3 doses of Infanrix™-IPV at 2, 4 and 6 months of age as an intramuscular injection into the anterolateral thigh.

    Arm title
    Infanrix + IMOVAX Polio Group
    Arm description
    -
    Arm type
    Active comparator

    Investigational medicinal product name
    Infanrix™
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Subjects received 3 doses of Infanrix™ co-administered with IMOVAX Polio® at 2, 4 and 6 months of age as an intramuscular injection into the anterolateral sides of opposite thighs.

    Investigational medicinal product name
    IMOVAX Polio®
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Subjects received 3 doses of Infanrix™ co-administered with IMOVAX Polio® at 2, 4 and 6 months of age as an intramuscular injection into the anterolateral sides of opposite thighs.

    Number of subjects in period 1 [1]
    Infanrix-IPV Group Infanrix + IMOVAX Polio Group
    Started
    224
    228
    Completed
    217
    223
    Not completed
    7
    5
         Unspecified
    -
    1
         Consent withdrawn by subject
    6
    4
         Lost to follow-up
    1
    -
    Notes
    [1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
    Justification: Of the 458 subjects enrolled in the study, 6 subjects (5 from Infanrix-IPV Group and 1 from Infanrix + IMOVAX Polio Group) were not administered the study vaccine due to consent withdrawal from parents/guardians and received an elimination code.

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Infanrix-IPV Group
    Reporting group description
    -

    Reporting group title
    Infanrix + IMOVAX Polio Group
    Reporting group description
    -

    Reporting group values
    Infanrix-IPV Group Infanrix + IMOVAX Polio Group Total
    Number of subjects
    224 228 452
    Age categorical
    Units: Subjects
        In utero
    0
        Preterm newborn infants (gestational age < 37 wks)
    0
        Newborns (0-27 days)
    0
        Infants and toddlers (28 days-23 months)
    0
        Children (2-11 years)
    0
        Adolescents (12-17 years)
    0
        Adults (18-64 years)
    0
        From 65-84 years
    0
        85 years and over
    0
    Age continuous
    Units: weeks
        arithmetic mean (standard deviation)
    8.8 ± 0.9 8.8 ± 0.91 -
    Gender categorical
    Units: Subjects
        Female
    112 110 222
        Male
    112 118 230

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Infanrix-IPV Group
    Reporting group description
    -

    Reporting group title
    Infanrix + IMOVAX Polio Group
    Reporting group description
    -

    Primary: Number of subjects with anti-diphtheria (anti-D) and anti-tetanus (anti-T) antibodies above the cut-off.

    Close Top of page
    End point title
    Number of subjects with anti-diphtheria (anti-D) and anti-tetanus (anti-T) antibodies above the cut-off.
    End point description
    End point type
    Primary
    End point timeframe
    One month after the three-dose primary vaccination course.
    End point values
    Infanrix-IPV Group Infanrix + IMOVAX Polio Group
    Number of subjects analysed
    204
    211
    Units: Subjects
        Anti-D ≥ 0.1 IU/mL (N=204; 211)
    204
    211
        Anti-T≥ 0.1 IU/mL (N=204; 211)
    204
    211
    Statistical analysis title
    Non-inferiority in terms of vaccine response to D
    Comparison groups
    Infanrix-IPV Group v Infanrix + IMOVAX Polio Group
    Number of subjects included in analysis
    415
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority [1]
    Method
    Parameter type
    Difference in seroprotection rate
    Point estimate
    0
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.85
         upper limit
    1.79
    Notes
    [1] - To assess the Non-inferiority of the Infanrix-IPV Group compared to the Infanrix + IMOVAX Polio Group in terms of vaccine response to diphtheria, standardized asymptotic 95% CI for the groups’difference (Infanrix-IPV Group minus Infanrix + IMOVAX Polio Group) was computed. Objective of non-inferiority was met since the LL of the 95% CI was above -10%.
    Statistical analysis title
    Non-inferiority in terms of vaccine response to T
    Comparison groups
    Infanrix-IPV Group v Infanrix + IMOVAX Polio Group
    Number of subjects included in analysis
    415
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority [2]
    Method
    Parameter type
    Difference in seroprotection rate
    Point estimate
    0
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.85
         upper limit
    1.79
    Notes
    [2] - To assess the Non-inferiority of the Infanrix-IPV Group compared to the Infanrix + IMOVAX Polio Group in terms of vaccine response to tetanus, standardized asymptotic 95% CI for the groups’difference (Infanrix-IPV Group minus Infanrix + IMOVAX Polio Group) was computed. Objective of non-inferiority was met since the LL of the 95% CI was above -10%.

    Primary: Number of subjects with anti-poliovirus (anti-polio) types 1, 2 and 3 above the cut-off.

    Close Top of page
    End point title
    Number of subjects with anti-poliovirus (anti-polio) types 1, 2 and 3 above the cut-off.
    End point description
    End point type
    Primary
    End point timeframe
    One month after the three-dose primary vaccination course.
    End point values
    Infanrix-IPV Group Infanrix + IMOVAX Polio Group
    Number of subjects analysed
    204
    207
    Units: Subjects
        Anti-polio 1 ≥ 8 (N=204; 207)
    204
    207
        Anti-polio 2 ≥ 8 (N=204; 205)
    204
    204
        Anti-polio 3 ≥ 8 (N=204; 207)
    203
    206
    Statistical analysis title
    Immune response non-inferiority - Anti-Polio 1
    Comparison groups
    Infanrix-IPV Group v Infanrix + IMOVAX Polio Group
    Number of subjects included in analysis
    411
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority [3]
    Method
    Parameter type
    Difference in seroprotection rate
    Point estimate
    0
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.85
         upper limit
    1.82
    Notes
    [3] - To assess the Non-inferiority of the Infanrix-IPV Group compared to the Infanrix + IMOVAX Polio Group in terms of vaccine response to poliovirus type 1, standardized asymptotic 95% CI for the groups’ difference (Infanrix-IPV Group minus Infanrix + IMOVAX Polio Group) was computed. Objective of non-inferiority was met since the LL of the 95% CI was above -10%.
    Statistical analysis title
    Immune response non-inferiority - Anti-Polio 2
    Comparison groups
    Infanrix-IPV Group v Infanrix + IMOVAX Polio Group
    Number of subjects included in analysis
    411
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority [4]
    Method
    Parameter type
    Difference in seroprotection rate
    Point estimate
    0.49
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.36
         upper limit
    2.71
    Notes
    [4] - To assess the Non-inferiority of the Infanrix-IPV Group compared to the Infanrix + IMOVAX Polio Group in terms of vaccine response to poliovirus type 2, standardized asymptotic 95% CI for the groups’ difference (Infanrix-IPV Group minus Infanrix + IMOVAX Polio Group) was computed. Objective of non-inferiority was met since the LL of the 95% CI was above -10%.
    Statistical analysis title
    Immune response non-inferiority - Anti-Polio 3
    Comparison groups
    Infanrix-IPV Group v Infanrix + IMOVAX Polio Group
    Number of subjects included in analysis
    411
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority [5]
    Method
    Parameter type
    Difference in seroprotection rate
    Point estimate
    -0.01
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -2.28
         upper limit
    2.24
    Notes
    [5] - To assess the Non-inferiority of the Infanrix-IPV Group compared to the Infanrix + IMOVAX Polio Group in terms of vaccine response to poliovirus type 3, standardized asymptotic 95% CI for the groups’ difference (Infanrix-IPV Group minus Infanrix + IMOVAX Polio Group) was computed. Objective of non-inferiority was met since the LL of the 95% CI was above -10%.

    Primary: Number of subjects with anti-pertussis toxoid (anti-PT), anti-pertactin (anti-PRN) and anti-filamentous haemagglutinin (anti-FHA) antibodies above the cut-off.

    Close Top of page
    End point title
    Number of subjects with anti-pertussis toxoid (anti-PT), anti-pertactin (anti-PRN) and anti-filamentous haemagglutinin (anti-FHA) antibodies above the cut-off.
    End point description
    End point type
    Primary
    End point timeframe
    One month after the three-dose primary vaccination course.
    End point values
    Infanrix-IPV Group Infanrix + IMOVAX Polio Group
    Number of subjects analysed
    204
    211
    Units: Subjects
        Anti-PT ≥ 5 EL.U/mL
    204
    211
        Anti-FHA ≥ 5 EL.U/mL
    204
    211
        Anti-PRN ≥ 5 EL.U/mL
    204
    210
    Statistical analysis title
    Immune response non-inferiority - Anti-PT
    Comparison groups
    Infanrix + IMOVAX Polio Group v Infanrix-IPV Group
    Number of subjects included in analysis
    415
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority [6]
    Method
    Parameter type
    Difference in seroprotection rate
    Point estimate
    1.44
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.46
         upper limit
    4.13
    Notes
    [6] - To assess the Non-inferiority of the Infanrix-IPV Group compared to the Infanrix + IMOVAX Polio Group in terms of vaccine response to pertussis toxoid, standardized asymptotic 95% CI for the groups’ difference (Infanrix-IPV Group minus Infanrix + IMOVAX Polio Group) was computed. Objective of non-inferiority was met since the LL of the 95% CI was above -10%.
    Statistical analysis title
    Immune response non-inferiority - Anti-FHA
    Comparison groups
    Infanrix-IPV Group v Infanrix + IMOVAX Polio Group
    Number of subjects included in analysis
    415
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority [7]
    Method
    Parameter type
    Difference in seroprotection rate
    Point estimate
    0.45
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.88
         upper limit
    2.95
    Notes
    [7] - To assess the Non-inferiority of the Infanrix-IPV Group compared to the Infanrix + IMOVAX Polio Group in terms of vaccine response to filamentous haemagglutinin, standardized asymptotic 95% CI for the groups’ difference (Infanrix-IPV Group minus Infanrix + IMOVAX Polio Group) was computed. Objective of non-inferiority was met since the LL of the 95% CI was above -10%.
    Statistical analysis title
    Immune response non-inferiority - Anti-PRN
    Comparison groups
    Infanrix + IMOVAX Polio Group v Infanrix-IPV Group
    Number of subjects included in analysis
    415
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority [8]
    Method
    Parameter type
    Difference in seroprotection rate
    Point estimate
    0.47
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.4
         upper limit
    2.64
    Notes
    [8] - To assess the Non-inferiority of the Infanrix-IPV Group compared to the Infanrix + IMOVAX Polio Group in terms of vaccine response to pertactin, standardized asymptotic 95% CI for the groups’ difference (Infanrix-IPV Group minus Infanrix + IMOVAX Polio Group) was computed. Objective of non-inferiority was met since the LL of the 95% CI was above -10%.

    Primary: Number of subjects with vaccine response to PT, PRN and FHA.

    Close Top of page
    End point title
    Number of subjects with vaccine response to PT, PRN and FHA. [9]
    End point description
    The subjects were initially (i.e. before vaccination) seronegative (i.e. with concentrations < 5 EL.U/mL), or at least maintenance of pre-vaccination antibody concentrations in subjects who are initially seropositive (i.e. with concentrations ≥ 5 EL.U/mL value).
    End point type
    Primary
    End point timeframe
    One month after the three-dose primary vaccination course.
    Notes
    [9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    Infanrix-IPV Group Infanrix + IMOVAX Polio Group
    Number of subjects analysed
    202
    211
    Units: Subjects
        Anti-PT (N=200; 209)
    200
    206
        Anti-FHA (N=202; 211)
    201
    209
        Anti-PRN (N=202; 211)
    202
    210
    No statistical analyses for this end point

    Secondary: Number of subjects with anti-D and anti-T antibodies above the cut-offs.

    Close Top of page
    End point title
    Number of subjects with anti-D and anti-T antibodies above the cut-offs.
    End point description
    End point type
    Secondary
    End point timeframe
    Before the first dose at the first study visit and one month after the three-dose primary vaccination course.
    End point values
    Infanrix-IPV Group Infanrix + IMOVAX Polio Group
    Number of subjects analysed
    204
    212
    Units: Subjects
        Anti-D, PRE, ≥ 1 IU/mL (N=202; 212)
    0
    0
        Anti-D, POST, ≥ 1 IU/mL (N=204; 211)
    194
    187
        Anti-T, PRE, ≥ 1 IU/mL (N=202; 212)
    1
    1
        Anti-T, POST, ≥ 1 IU/mL (N=204; 211)
    204
    208
    No statistical analyses for this end point

    Secondary: Concentrations for anti-D and anti-T.

    Close Top of page
    End point title
    Concentrations for anti-D and anti-T.
    End point description
    End point type
    Secondary
    End point timeframe
    Before the first dose at the first study visit and one month after the three-dose primary vaccination course.
    End point values
    Infanrix-IPV Group Infanrix + IMOVAX Polio Group
    Number of subjects analysed
    204
    212
    Units: IU/mL
    geometric mean (confidence interval 95%)
        Anti-D, PRE (N=202; 212)
    0.052 (0.051 to 0.054)
    0.053 (0.05 to 0.055)
        Anti-D, POST (N=204; 211)
    4.333 (3.902 to 4.813)
    2.63 (2.36 to 2.932)
        Anti-T, PRE (N=202; 212)
    0.059 (0.055 to 0.064)
    0.06 (0.056 to 0.065)
        Anti-T, POST (N=204; 211)
    10.306 (9.5 to 11.18)
    7.139 (6.512 to 7.826)
    No statistical analyses for this end point

    Secondary: Titers for anti-polio 1, 2 and 3.

    Close Top of page
    End point title
    Titers for anti-polio 1, 2 and 3.
    End point description
    End point type
    Secondary
    End point timeframe
    Before the first dose at the first study visit and one month after the three-dose primary vaccination course.
    End point values
    Infanrix-IPV Group Infanrix + IMOVAX Polio Group
    Number of subjects analysed
    204
    212
    Units: Titers
    geometric mean (confidence interval 95%)
        Anti-polio 1, PRE (N=199; 212)
    6.3 (5.5 to 7.1)
    6.1 (5.4 to 6.9)
        Anti-polio 1, POST (N=204; 207)
    755.5 (643.5 to 887.4)
    263 (232.1 to 298)
        Anti-polio 2, PRE (N=202; 211)
    5.8 (5.2 to 6.5)
    6.5 (5.8 to 7.3)
        Anti-polio 2, POST (N=204; 205)
    704.7 (599.5 to 828.4)
    267.6 (233.4 to 306.8)
        Anti-polio 3, PRE (N=202; 212)
    5 (4.5 to 5.4)
    4.9 (4.5 to 5.3)
        Anti-polio 3, POST (N=204; 207)
    1209.5 (1040.1 to 1406.5)
    438.3 (383.1 to 501.3)
    No statistical analyses for this end point

    Secondary: Concentrations for anti-PT, anti-FHA and anti-PRN.

    Close Top of page
    End point title
    Concentrations for anti-PT, anti-FHA and anti-PRN.
    End point description
    End point type
    Secondary
    End point timeframe
    Before the first dose at the first study visit and one month after the three-dose primary vaccination course.
    End point values
    Infanrix-IPV Group Infanrix + IMOVAX Polio Group
    Number of subjects analysed
    204
    212
    Units: EL.U/mL
    geometric mean (confidence interval 95%)
        Anti-PT, PRE (N=200; 210)
    3 (2.8 to 3.2)
    3.2 (3 to 3.5)
        Anti-PT, POST (N=204; 211)
    63.3 (58.7 to 68.2)
    55.6 (50.9 to 60.7)
        Anti-FHA, PRE (N=202; 212)
    7.4 (6.5 to 8.4)
    8.5 (7.4 to 9.7)
        Anti-FHA, POST (N=204; 211)
    294.3 (269.5 to 321.4)
    259.6 (235.1 to 286.6)
        Anti-PRN, PRE (N=202; 212)
    2.7 (2.5 to 2.8)
    2.7 (2.6 to 2.9)
        Anti-PRN, POST (N=204; 211)
    205 (187.7 to 223.9)
    155.6 (140.7 to 172.1)
    No statistical analyses for this end point

    Secondary: Number of subjects reporting solicited local symptoms.

    Close Top of page
    End point title
    Number of subjects reporting solicited local symptoms.
    End point description
    End point type
    Secondary
    End point timeframe
    During the 4-day (Day 0-3) follow up period after vaccination.
    End point values
    Infanrix-IPV Group Infanrix + IMOVAX Polio Group
    Number of subjects analysed
    220
    226
    Units: Subjects
        Any Pain
    92
    96
        Any Redness
    115
    116
        Any Swelling
    74
    79
    No statistical analyses for this end point

    Secondary: Number of subjects reporting solicited general symptoms.

    Close Top of page
    End point title
    Number of subjects reporting solicited general symptoms.
    End point description
    End point type
    Secondary
    End point timeframe
    During the 4-day (Day 0-3) follow up period after vaccination.
    End point values
    Infanrix-IPV Group Infanrix + IMOVAX Polio Group
    Number of subjects analysed
    221
    226
    Units: Subjects
        Any Drowsiness
    95
    99
        Any Fever (axillary)
    63
    38
        Any Irritability
    140
    139
        Any Loss of appetite
    84
    78
    No statistical analyses for this end point

    Secondary: Number of subjects reporting any unsolicited adverse events (AEs).

    Close Top of page
    End point title
    Number of subjects reporting any unsolicited adverse events (AEs).
    End point description
    End point type
    Secondary
    End point timeframe
    During the 31-day (Day 0-30) follow-up period after vaccination.
    End point values
    Infanrix-IPV Group Infanrix + IMOVAX Polio Group
    Number of subjects analysed
    224
    228
    Units: Subjects
        Any AE(s)
    135
    138
    No statistical analyses for this end point

    Secondary: Number of subjects reporting any serious adverse events (SAEs).

    Close Top of page
    End point title
    Number of subjects reporting any serious adverse events (SAEs).
    End point description
    End point type
    Secondary
    End point timeframe
    During the entire study period.
    End point values
    Infanrix-IPV Group Infanrix + IMOVAX Polio Group
    Number of subjects analysed
    224
    228
    Units: Subjects
        Any SAE(s)
    15
    17
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Solicited symptoms during the 4-day post-vaccination period, Unsolicited AEs during the 31-day post-vaccination period and SAEs during the entire period
    Assessment type
    Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    10.1
    Reporting groups
    Reporting group title
    Infanrix-IPV Group
    Reporting group description
    -

    Reporting group title
    Infanrix + IMOVAX Polio Group
    Reporting group description
    -

    Serious adverse events
    Infanrix-IPV Group Infanrix + IMOVAX Polio Group
    Total subjects affected by serious adverse events
         subjects affected / exposed
    15 / 224 (6.70%)
    17 / 228 (7.46%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    Congenital, familial and genetic disorders
    Patent ductus arteriosus
         subjects affected / exposed
    0 / 224 (0.00%)
    1 / 228 (0.44%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nervous system disorders
    Febrile convulsion
         subjects affected / exposed
    1 / 224 (0.45%)
    0 / 228 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Pyrexia
         subjects affected / exposed
    2 / 224 (0.89%)
    1 / 228 (0.44%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Inguinal hernia
         subjects affected / exposed
    0 / 224 (0.00%)
    2 / 228 (0.88%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Hepatic function abnormal
         subjects affected / exposed
    1 / 224 (0.45%)
    0 / 228 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Bronchiolitis
         subjects affected / exposed
    7 / 224 (3.13%)
    3 / 228 (1.32%)
         occurrences causally related to treatment / all
    0 / 7
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    4 / 224 (1.79%)
    5 / 228 (2.19%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    3 / 224 (1.34%)
    5 / 228 (2.19%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastroenteritis
         subjects affected / exposed
    2 / 224 (0.89%)
    2 / 228 (0.88%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Kawasaki’s disease
         subjects affected / exposed
    0 / 224 (0.00%)
    1 / 228 (0.44%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Otitis media acute
         subjects affected / exposed
    1 / 224 (0.45%)
    0 / 228 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pyelonephritis acute
         subjects affected / exposed
    1 / 224 (0.45%)
    0 / 228 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Sepsis
         subjects affected / exposed
    1 / 224 (0.45%)
    0 / 228 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Infanrix-IPV Group Infanrix + IMOVAX Polio Group
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    140 / 224 (62.50%)
    139 / 228 (60.96%)
    General disorders and administration site conditions
    Pain
    alternative assessment type: Systematic
         subjects affected / exposed
    92 / 224 (41.07%)
    96 / 228 (42.11%)
         occurrences all number
    92
    96
    Redness
    alternative assessment type: Systematic
         subjects affected / exposed
    115 / 224 (51.34%)
    116 / 228 (50.88%)
         occurrences all number
    115
    116
    Swelling
    alternative assessment type: Systematic
         subjects affected / exposed
    74 / 224 (33.04%)
    79 / 228 (34.65%)
         occurrences all number
    74
    79
    Drowsiness
    alternative assessment type: Systematic
         subjects affected / exposed
    95 / 224 (42.41%)
    99 / 228 (43.42%)
         occurrences all number
    95
    99
    Fever (Axillary)
    alternative assessment type: Systematic
         subjects affected / exposed
    63 / 224 (28.13%)
    38 / 228 (16.67%)
         occurrences all number
    63
    38
    Irritability
    alternative assessment type: Systematic
         subjects affected / exposed
    140 / 224 (62.50%)
    139 / 228 (60.96%)
         occurrences all number
    140
    139
    Loss of appetite
         subjects affected / exposed
    84 / 224 (37.50%)
    78 / 228 (34.21%)
         occurrences all number
    84
    78
    Diarrhea
         subjects affected / exposed
    12 / 224 (5.36%)
    8 / 228 (3.51%)
         occurrences all number
    12
    8
    Pyrexia
         subjects affected / exposed
    17 / 224 (7.59%)
    0 / 228 (0.00%)
         occurrences all number
    17
    0
    Skin and subcutaneous tissue disorders
    Dermatitis atopic
         subjects affected / exposed
    16 / 224 (7.14%)
    17 / 228 (7.46%)
         occurrences all number
    16
    17
    Infections and infestations
    Upper respiratory tract infection
         subjects affected / exposed
    72 / 224 (32.14%)
    61 / 228 (26.75%)
         occurrences all number
    72
    61
    Gastroenteritis
         subjects affected / exposed
    12 / 224 (5.36%)
    14 / 228 (6.14%)
         occurrences all number
    12
    14
    Bronchiolitis
         subjects affected / exposed
    16 / 224 (7.14%)
    9 / 228 (3.95%)
         occurrences all number
    16
    9
    Bronchitis
         subjects affected / exposed
    7 / 224 (3.13%)
    12 / 228 (5.26%)
         occurrences all number
    7
    12

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    27 Oct 2005
    This amendment was written to reflect the changes in study design following discussions with KFDA, ad to clarify some study aspects. Major changes in study design being: - Usage of IMOVAX Polio™ instead of IPOL® in the study. Both vaccines are manufactured by Sanofi-Pasteur and both have the same content. IMOVAX Polio™ will be used instead of IPOL® in order to source the vaccine supply directly from Belgium instead of the United States. - Perform Hib vaccine administration out of the study context. - Inclusion of vaccine response to pertussis antigens as a primary endpoint and recalculation of sample size accordingly.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2019 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA